Join the club for FREE to access the whole archive and other member benefits.

Turn Bio raised funds to usher epigenetic reprogramming from bench to bedside

11-Apr-2022

Key points from article :

Turn Biotechnologies closed fundraising round primed to usher the company into its next stage of development.

Platform is based on using mRNA technology to develop novel medicines to combat age-related diseases.

Company licensed epigenetic reprogramming of age (ERATM) technology from Stanford University in Jan 2021.

"It is non-integrative, [] – so we avoid the risk of harmful mutations,” said Vittorio Sebastiano, co-founder of Turn Bio.

Funding will help to achieve in vivo data results and to advance additional indications more rapidly in the pipeline.

Pipeline candidates are still in the preclinical stage but Anja Krammer, CEO of Turn Bio is hopeful to advance toward clinic in 2023.

He emphasized the goal is to impact the health span of people, ameliorate their quality of life, feeling healthy and strong.

Its the first company to demonstrate that epigenetic resetting of aging is possible in human cells.

Results backing the mRNA tech is published in Nature Communications in 2019 led by Sebastiano.






mRNA technology-reset aging to extend health span and improve quality of life

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

CEO at Turn Biotechnologies

Company

Innovation in ophthalmology with addition of novel gene therapy program for glaucoma

Journal

Journal covering all topics in physics, chemistry, and biology.

Company

Focused on restoring cells’ youthful vigor to repair damage caused by the aging process

Academic

Assistant Professor of Obstetric and Gynaecology at the Stanford University School of Medicine